MedTrace Logo

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

NCT04693897 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-01-27

No results posted yet for this study

Summary

About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects. While beta-3 adrenoceptor agonist, Mirabegron, has far fewer side effects, there are no consensus on whether it can be used as first-line treatment. The investigator's preliminary study showed that the concentration of beta-3 adrenoceptor in the urine of OAB patients is higher than that in the normal control group, so comparing urinary beta-3 adrenoceptor concentration of OAB patients before and after treatment may be used as a biomarker of therapeutic effectiveness. The results of this study will be of great help in understanding the effectiveness of Mirabegron and formulating OAB treatment plans.

Conditions

  • Overactive Bladder Syndrome
  • Detrusor Overactivity

Interventions

DRUG

Mirabegron 50 MG

Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome

DRUG

Solifenacin Succinate 5 MG

Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04693897 on ClinicalTrials.gov